

Dear editors,

We thank you for the kind review, and most importantly, the opportunity to revise our manuscript (70598) now titled “Efficacy and Safety of Sofosbuvir/Velpatasvir with or without ribavirin in Hepatitis C Genotype 3 compensated cirrhosis: A meta-analysis”.

Our point-to-point responses to the reviewers are as below. The revised version of the manuscript is attached for your review.

### **Reviewer 1 (Science editor)**

Comment 1: “Subgroup analysis showed that ribavirin was associated with a higher SVR12 in GT3 compensated cirrhosis patients with baseline resistance-associated substitutions (RAS).” The authors should mention that most of the patients assessed for RAS were from the report from Esteban and there was no statistical significance. They should mention these in Discussion as the limitation.

*Response 1: We thank you for your comment. We agree, and had incorporated the suggestion in our revised manuscript in page 10, para 4, line 2-3, as follows:*

*“The number of subjects with baseline RAS mutations tested were small and only derived from two studies [16,22]. Although the SVR12 was numerically higher in ribavirin group, it did not achieve statistical significance”.*

Comment 2 (P6, line 23): “Ribavirin” should be “ribavirin (RBV)”, since this is the 1st appearance. After this, RBV should be used.

*Response 2: Thank you for the comment. We had revise the manuscript in page 6, para 3, line 1-2, as advised.*

*“The potential of ribavirin (RBV) as add-on therapy to SOF/VEL to improve SVR12 in HCV patients remains an area of interest.”*

### **Reviewer 2**

*We thank the reviewer for the comment and taking time to review our manuscript.*

### **Review by Company editor-in-chief**

Comment 1: The title of the manuscript is too long and must be shortened to meet the requirement of the journal (Title: The title should be no more than 18 words).

*Response 1: Thank you for the comment. We have changed the title as the following: “Safety and Efficacy of Sofosbuvir/Velpatasvir with or without ribavirin in Hepatitis C Genotype 3 compensated cirrhosis: A meta-analysis”.*

Comment 2: Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. Authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are

hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content.

Please upload the approved grant application form(s) or funding agency copy of any approval document(s).

*Response 2: All necessary documents has been attached for your reference.*

We wish to thank the editor and reviewers for their time and invaluable comments to improve our manuscript. We hope that our revised manuscript is now acceptable for publication in your esteemed journal.

Sincerely,

Dr Wong Yu Jun